Electromed, Inc. Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended March 31, 2023. The request identifies “2022 Q3,” but the filing is for fiscal 2023 Q3. Financial statements are unaudited.
Business Context
Electromed develops, manufactures and markets SmartVest airway-clearance systems using high-frequency chest wall oscillation therapy. Products are sold primarily in the U.S. home-care and institutional markets, with additional distributor-based international sales. The company launched its newest SmartVest Clearway system to the U.S. home-care market in March 2023 after receiving FDA 510(k) clearance in December 2022.
Financial Performance and Liquidity
| Metric | Three Months Ended March 31 | Nine Months Ended March 31 |
|---|---|---|
| Net revenues | $12.068 million, up 19.0% | $34.455 million, up 13.4% |
| Gross profit | $9.056 million | $26.069 million |
| Gross margin | 75.0%, versus 76.4% | 75.7%, versus 76.7% |
| Operating income | $1.196 million | $2.514 million |
| Net income | $1.075 million, versus $0.645 million | $2.133 million, versus $1.922 million |
| Diluted earnings per share | $0.12, versus $0.07 | $0.25, versus $0.22 |
| Operating cash flow | Not provided separately for the quarter | $0.316 million, versus $0.053 million |
Home-care revenue increased 21.5% in the quarter and 13.0% year to date, driven primarily by higher referrals and approvals. Nine-month institutional revenue increased 21.0% and home-care distributor revenue increased 30.9%, while international revenue declined 28.5%.
Cash and cash equivalents were $6.776 million at March 31, 2023, compared with $8.153 million at June 30, 2022. Working capital was $28.752 million. Accounts receivable increased to $22.345 million from $21.052 million, and contract assets increased to $0.570 million from $0.286 million.
The company used $1.275 million in investing activities, primarily for $1.221 million of property and equipment expenditures, and $0.418 million in financing activities. Financing uses included $0.305 million of taxes paid on net share settlement of option exercises and $0.153 million of share repurchases.
There was no outstanding balance under the $2.5 million revolving credit facility, and the full amount was available at March 31, 2023. The facility expires on December 18, 2023 if not renewed and is subject to financial and nonfinancial covenants.
Material Changes Versus the Prior Comparable Period
- Revenue growth accelerated, with quarterly revenue up 19.0% and year-to-date revenue up 13.4%.
- Gross margin declined because of higher material costs and component-broker fees associated with ramping Clearway production.
- SG&A increased 17.6% for the quarter and 15.8% year to date, primarily from expanded sales, reimbursement, marketing and support staffing.
- Research and development expense declined 50.6% for the quarter and 40.6% year to date as Clearway development was completed.
- Net income improved despite higher SG&A and production costs, aided by revenue growth, lower R&D expense and a lower effective tax rate. The nine-month effective tax rate was 16.4%, compared with 23.1% in the prior year.
- Operating cash flow improved year to date but remained modest relative to net income because of increases in receivables, contract assets and inventory, and decreases in accrued compensation.
- The company repurchased 239,995 shares for an aggregate $2.725 million under its authorization as of March 31, 2023. No shares were repurchased during the quarter.
Guidance, Outlook, Risks and Unusual Items
- Management expects the CMS COVID-19 waiver for certain Medicare respiratory-device requirements to terminate no later than May 11, 2023. The company expects possible delays in Medicare approvals, cancellations or appeals, which could reduce future revenue growth.
- Management is adding employees and re-educating clinicians to mitigate the effect of the waiver expiration.
- Supply-chain interruptions affected product availability from September 2022 through March 2023 and could continue through the fourth quarter of fiscal 2023. Elevated material costs and shipping rates are expected through the fourth quarter of fiscal 2023 and the first half of fiscal 2024.
- Management identified potential risks from component shortages, inflation, ERP implementation, reimbursement changes, regulatory compliance, competition, cybersecurity incidents, international regulation and renewal of the credit facility.
- A putative class action related to a previously disclosed data breach was preliminarily approved for settlement in January 2023. Final approval was scheduled for June 5, 2023; the filing states that ultimate outcome and potential loss exposure could not be determined.
- The filing provides no specific full-year revenue or earnings guidance. Management believes cash, operating cash flow and available credit will fund fiscal 2023 working-capital and capital-expenditure needs.
Important Facts for Investors to Verify
- Whether Medicare referral and approval trends deteriorate after the CMS waiver ends.
- Whether Clearway production reaches demand without further supply interruptions, broker fees or margin pressure.
- Collections and aging of the $22.345 million accounts receivable balance and realization of the $0.570 million contract-asset balance.
- Renewal or replacement of the $2.5 million credit facility before its December 18, 2023 expiration.
- Final court approval and any settlement payment or other exposure related to the data-breach litigation.
- Whether revenue growth converts into stronger operating cash flow after capital expenditures and working-capital investment.